<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Expression of genes coding for OASS-A and OASS-B have already been correlated with antibiotic resistance in 
 <italic class="italic">Salmonella</italic>, being the knock-out strains more susceptible to antibiotics
 <xref rid="CIT0002" ref-type="bibr" class="xref">
  <sup class="sup">2</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0004" ref-type="bibr" class="xref">
  <sup class="sup">4</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0010" ref-type="bibr" class="xref">
  <sup class="sup">10</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0011" ref-type="bibr" class="xref">
  <sup class="sup">11</sup>
 </xref>. Given these findings, we have explored the potential of cysteine biosynthesis shutdown as a strategy to obtain new adjuvants of antibacterial agents
 <xref rid="CIT0001" ref-type="bibr" class="xref">
  <sup class="sup">1</sup>
 </xref>
 <sup class="sup">,</sup>
 <xref rid="CIT0002" ref-type="bibr" class="xref">
  <sup class="sup">2</sup>
 </xref>. The first peptide inhibitors of 
 <italic class="italic">Haemophilus influenzae</italic> OASS (HiOASS) were designed based on the C-terminal sequence of SAT, which acts as the physiological inhibitor of OASS
 <xref rid="CIT0012" ref-type="bibr" class="xref">
  <sup class="sup">12</sup>
 </xref>. Later, peptidomimetic compounds were designed in which the carboxylic acid moiety and the hydrophobic motif of the final amino acid isoleucine were considered critical features for OASS binding, therefore both were kept as structural motives of small-molecule inhibitors (compound 
 <bold class="bold">I,</bold>
 <xref ref-type="fig" rid="F0001" class="xref">Figure 1)</xref>. After these first speculative attempts, several rounds of optimisation of compound 
 <bold class="bold">I</bold> led to the discovery of a number of derivatives, culminating with compound 
 <bold class="bold">II</bold> (
 <xref ref-type="fig" rid="F0001" class="xref">Figure 1</xref>), to our knowledge the most potent inhibitor of bacterial OASS described so far
 <xref rid="CIT0013" ref-type="bibr" class="xref">
  <sup class="sup">13</sup>
 </xref>.
</p>
